Supreme Court Rules FIFRA Preempts State Cancer‑Warning Claim in Monsanto v. Durnell
Recent Supreme Court Coverage
- Supreme Court Grants Stay, Finds Historic Preservation Group Lacks Article III Standing September 1, 2026
- Supreme Court Grants Stay in Trump v. California, Finding States Lack Standing to Challenge Executive Order August 25, 2026
- Supreme Court Holds Rooker‑Feldman Bars Federal Review of Pending State Court Judgments July 25, 2026
- Supreme Court Reverses Second Circuit Habeas Relief in Hernandez, Citing AEDPA Limits July 25, 2026
- Supreme Court Rules Auction Sale Price Governs Just Compensation in Tax Sale Takings Case July 24, 2026
Plain-English Summary
John Durnell sued Monsanto in Missouri for failing to warn that Roundup could cause cancer. The jury awarded him damages, and the Missouri Court of Appeals affirmed, rejecting Monsanto's preemption argument. The Supreme Court reversed, finding that FIFRA’s preemption clause bars the state tort claim because it would require a label change beyond EPA’s approval. The decision was issued by Justice Kavanaugh with a 7‑2 majority.
Legal Question
Whether a state‑law failure‑to‑warn claim that obliges a pesticide manufacturer to add a cancer warning to a product’s label is preempted by the Federal Insecticide, Fungicide, and Rodenticide Act’s “Uniformity” clause, 7 U.S.C. §136v(b), and related Supreme Court precedent on federal preemption such as Riegel v. Medtronic.
Holding
The Court held that FIFRA expressly preempts Durnell’s state‑law claim because it would require Monsanto to add a cancer warning that differs from the EPA‑approved label. The opinion was delivered by Justice Kavanaugh, joined by Chief Justice Roberts and Justices Thomas, Alito, Sotomayor, Kagan, and Barrett, for a 7‑2 majority. Justice Jackson filed a dissent, joined by Justice Gorsuch. The Court reversed and remanded the Missouri appellate decision.
Reasoning
The Court began by noting that EPA has repeatedly concluded glyphosate is not likely to cause cancer and therefore has not required a cancer warning on Roundup’s label. Under FIFRA, EPA must approve a pesticide label as “necessary and adequate” and manufacturers must use that label until EPA approves a change (7 U.S.C. §136a(f)(1); 40 CFR §152.44(a)). The statute’s preemption clause bars any state labeling requirement that is “in addition to or different from” the federal requirement. Because Durnell’s tort claim would compel Monsanto to add a cancer warning, it is precisely the type of requirement preempted by §136v(b). The Court relied on Riegel v. Medtronic, which held that FDA’s pre‑market approval imposed “requirements” that preempted state‑law safety claims, and applied the same analysis to EPA’s label approval. The Court rejected Durnell’s argument that state law merely requires adequate warnings, emphasizing that EPA’s comprehensive review makes the federal label the exclusive source of required warnings. It also dismissed Durnell’s reliance on §136a(f)(2), explaining that registration is only prima facie evidence of compliance and does not shield a manufacturer from preemption. Consequently, the state claim is barred.
Broader Impact
The decision narrows the ability of states to impose pesticide‑label warnings that diverge from EPA‑approved labels, likely curtailing future state‑law failure‑to‑warn suits involving pesticides. Lower courts must treat any state labeling requirement that adds to or changes an EPA label as preempted, reinforcing the uniformity goal of FIFRA. The ruling clarifies the scope of preemption under the “Uniformity” clause, resolving any lingering circuit disagreement on whether state tort claims can compel label changes. It also signals that courts will look to Riegel and similar preemption cases when evaluating state‑level safety claims against federal regulatory schemes. Future litigation may focus on whether new scientific evidence can prompt EPA to amend labels, rather than on state‑law avenues to impose additional warnings.
Sections beyond the plain-English summary are AI-synthesized analysis based on the available opinion excerpt from CourtListener, read, edited where needed, and approved by a human editor before publication. Full methodology: Editorial & Methodology.
← All Records